BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026

Rhea-AI Summary

BioHarvest Sciences (NASDAQ: BHST) will participate in the 38th Annual Roth Conference on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. CEO Ilan Sobel is scheduled for one-on-one meetings with institutional investors.

According to the company, BioHarvest completed a successful Q4 2025 financing, is fully funded for near-term CapEx, and has over 85,000 direct customers as it focuses on growth in CDMO and consumer product businesses.

News Market Reaction – BHST

-2.44%

1 alert

-2.44% News Effect

On the day this news was published, BHST declined 2.44%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 22–24, 2026 Conference edition: 38th Annual Direct customers: Over 85,000 +5 more

8 metrics

Conference dates March 22–24, 2026 38th Annual Roth Conference schedule

Conference edition 38th Annual Roth Conference for growth companies

Direct customers Over 85,000 BioHarvest Product-side customer base cited by CEO

Share price $4.51 Pre-news current price from market context

Daily move -4.25% 24h price change prior to article publication

52-week range $4.27–$12.80 Low and high from market context

Market cap $106,760,826 Equity value before this news

200-day MA $7.25 Long-term trend level; price trading below

Market Reality Check

Price: $4.20 Vol: Volume 34,928 is 1.57x th...

high vol

$4.20 Last Close

Volume Volume 34,928 is 1.57x the 20-day average of 22,240, indicating elevated trading interest ahead of the conference. high

Technical Shares at $4.51 are trading below the 200-day MA of $7.25 and sit 64.77% under the 52-week high.

Peers on Argus

BHST fell 4.25% while tracked peers were mixed: ABVE up 8.13%, DDC down 5.32%, a...

1 Up 1 Down

BHST fell 4.25% while tracked peers were mixed: ABVE up 8.13%, DDC down 5.32%, and others near flat. Momentum scanner shows LFVN up 7.08% and ATPC down 7.41%, reinforcing a stock-specific move for BHST.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Year-end update	Positive	+3.7%	Shared revenue run rate, margins, and profitability focus in shareholder letter.
Dec 18	Non-dilutive grant	Positive	+1.1%	Award of $1.6M Israeli Innovation Authority grant for platform development.
Dec 03	Product launch	Positive	+3.0%	Launch of VINIA Blood Flow Hydration into large U.S. electrolyte market.
Nov 13	Q3 2025 earnings	Neutral	-1.0%	Reported revenue growth, ongoing net loss, and Q4 guidance with EBITDA range.
Nov 12	Conference & raise	Positive	+14.8%	Conference attendance and highlight of upsized $19.9M equity offering.

Pattern Detected

Recent company updates on growth, grants, product launches, and capital raises generally coincided with positive share reactions, suggesting investors have rewarded execution and financing milestones.

Recent Company History

Over the past few months, BioHarvest reported Q3 2025 revenue of $9.1M with strong growth, launched the VINIA Blood Flow Hydration product into a $13B market, and secured a $1.6M Israeli Innovation Authority grant to advance its second-generation Botanical Synthesis platform. A year-end letter cited an annualized revenue run rate above US$36M and >85,000 VINIA users. Today’s conference-participation news fits this pattern of investor-outreach and growth-focused communication.

Market Pulse Summary

This announcement highlights BioHarvest’s participation in a major investor conference, positioning ...

Analysis

This announcement highlights BioHarvest’s participation in a major investor conference, positioning management to meet institutional investors and present its growth strategy. The company cites over 85,000 direct customers and an aim to accelerate both CDMO and consumer businesses after a Q4 2025 financing round. Historically, updates on growth, grants, and product launches have mattered for sentiment, so investors may watch for any new disclosures or targets shared around the event.

Key Terms

cdmo, capex

2 terms

cdmo technical

"focused on driving accelerated growth in both our CDMO and Consumer Product businesses."

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

capex financial

"we are now fully funded from a near-term CapEx perspective, and focused on driving accelerated growth"

Capex, short for capital expenditures, refers to the money a company spends to buy, upgrade, or maintain physical assets such as buildings, equipment, or technology. It matters to investors because these investments can help a company grow and improve its long-term performance, but they also represent significant costs that can impact profitability and cash flow.

AI-generated analysis. Not financial advice.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.

CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.

38th Annual Roth Conference for Growth Companies
Date: March 22-24, 2026
Location: The Ritz-Carlton Laguna Niguel- Dana Point, CA
Format: 1x1 Meetings

Sobel said: "I am pleased to announce our invitation to the 38th Annual Roth Conference, which is a high-profile opportunity to highlight the BioHarvest story for a select group of sophisticated investors. Our successful Q4 2025 financing round has us at an important inflection point, as we are now fully funded from a near-term CapEx perspective, and focused on driving accelerated growth in both our CDMO and Consumer Product businesses. With now over 85,000 direct customers on our Product side, and anchor CDMO research partnerships, we are well positioned to achieve significant growth milestones in 2026, leveraging novel plant-based compounds in our mission to improve human health and wellness."

Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact info@bioharvest.com.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286091

FAQ

When will BioHarvest Sciences (BHST) attend the 38th Annual Roth Conference in 2026?

BioHarvest will attend on March 22-24, 2026 with management meeting investors one-on-one. According to the company, CEO Ilan Sobel is scheduled for 1x1 meetings throughout the event to engage institutional investors and discuss strategy.

Who from BioHarvest (BHST) will meet investors at the Roth Conference on March 22-24, 2026?

CEO Ilan Sobel will host one-on-one meetings with institutional investors during the conference. According to the company, these 1x1 sessions aim to highlight BioHarvest's growth plan after its Q4 2025 financing round.

What is BioHarvest (BHST) highlighting at the March 2026 Roth Conference?

BioHarvest will emphasize its Botanical Synthesis platform, CDMO and consumer product growth focus. According to the company, messaging will reference its Q4 2025 financing and being fully funded for near-term CapEx.

Does BioHarvest (BHST) report recent financing or capitalization news ahead of the March 2026 Roth Conference?

Yes. The company said it completed a successful Q4 2025 financing and is fully funded for near-term CapEx needs. According to the company, this underpins plans to accelerate growth in 2026.

How large is BioHarvest's (BHST) consumer base mentioned for the Roth Conference presentation?

BioHarvest reported having over 85,000 direct customers on its product side. According to the company, this customer base supports its consumer product growth strategy and complements CDMO research partnerships.

How can investors schedule meetings with BioHarvest (BHST) at the March 22-24, 2026 Roth Conference?

Registration is mandatory and meetings must be scheduled in advance via the company contact. According to the company, investors should email info@bioharvest.com for more information or to arrange 1x1 meetings.